Aeglea BioTherapeutics Raises $12M; Joins Austin Technology Incubator

aegleaAeglea BioTherapeutics, an Austin, Texas-based early-stage drug development company working on novel cancer fighting treatments, recently raised $12m in financing.

The names of the backers were not disclosed.

The company, which has joined the Austin Technology Incubator (ATI), part of the IC2 Institute at The University of Texas at Austin (UT), will use the funds to continue to grow, add new staff, conduct research and manufacturing for the lead drug, and prepare for the first phase of clinical trials.

Led by David G Lowe, PhD, President and CEO, Aeglea BioTherapeutics is developing – in partnership with Dr. George Georgiou of The University of Texas at Austin – three drugs invented at UT, that degrade certain amino acids in the circulation, taking advantage of the cancer’s metabolic vulnerability, and selectively killing only the tumor.



Join the discussion